Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Cell Mol Neurobiol ; 35(2): 175-87, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25212824

RESUMEN

Glioblastoma multiforme (GBM) is one of the deadliest human malignancies. A cure for GBM remains elusive, and the overall survival time is less than 1 year. Thus, the development of more efficient therapeutic approaches for the treatment of these patients is required. Induction of tumor cell death by certain phytochemicals derived from medicinal herbs and dietary plants has become a new frontier for cancer therapy research. Although the cancer suppressive effect of Ficus carica (fig) latex (FCL) has been determined in a few cancer types, the effect of this latex on GBM tumors has not been investigated. Therefore, in the current study, the anti-proliferative activity of FCL and the effect of the FCL-temozolomide (TMZ) combination were tested in the T98G, U-138 MG, and U-87 MG GBM cell lines using the WST-1 assay. The mechanism of cell death was analyzed using Annexin-V/FITC and TUNEL assays, and the effect of FCL on invasion was tested using the chick chorioallantoic membrane assay. To determine the effect of FCL on GBM progression, the expression levels of 40 GBM associated miRNAs were analyzed in T98G cells using RT-qPCR. According to the obtained data, FCL causes cell death in GBM cells with different responses to TMZ, and this effect is synergistically increased in combination with TMZ. In addition, the current study is the first to demonstrate the effect of FCL on modulation of let-7d expression, which may be an important underlying mechanism of the anti-invasive effect of this extract.


Asunto(s)
Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patología , Ficus/química , Glioblastoma/genética , Glioblastoma/patología , Látex/uso terapéutico , MicroARNs/genética , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Fraccionamiento Químico , Dacarbazina/análogos & derivados , Dacarbazina/farmacología , Dacarbazina/uso terapéutico , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Etiquetado Corte-Fin in Situ , Látex/farmacología , MicroARNs/metabolismo , Modelos Biológicos , Invasividad Neoplásica , Neovascularización Fisiológica/efectos de los fármacos , Fitoterapia , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Temozolomida
2.
Respir Physiol Neurobiol ; 278: 103441, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32339697

RESUMEN

We previously reported that intracerebroventricularly (ICV) injected arachidonic acid (AA) could produce pressor and bradycardic responses on the cardiovascular system and hyperventilation effect on the respiratory system by activating cyclooxygenase (COX). We also demonstrated that centrally injected AA-induced cardiovascular and respiratory responses were mediated by COX-metabolites, such as thromboxane A2 (TXA2), prostaglandin (PG) D, PGE, and PGF2α. Brain tissue is also able to express the lipoxygenase (LOX) enzyme and LOX-induced AA-metabolites. The current study was designed to investigate the possible mediation of the central LOX pathway in AA-induced cardiorespiratory effects in anesthetized rats. Central pretreatment with different doses of a non-selective LOX inhibitor, nordihydroguaiaretic acid (NDGA) (500 and 1000 µg; ICV) partially blocked the AA (0.5 µmol; ICV)-evoked pressor and bradycardic cardiovascular responses in male anesthetized Sprague Dawley rats. Pretreatment with different doses of NDGA (500 and 1000 µg; ICV) also reduced AA-induced hyperventilation responses, with an increase in tidal volume, respiratory rate and minute ventilation, in the rats. Moreover, AA-induced increasing pO2 and decreasing pCO2 responses were diminished by central NDGA pretreatment. In summary, our findings show that the central LOX pathway might mediate, at least in part, centrally administered AA-evoked cardiorespiratory and blood gases responses.


Asunto(s)
Ácido Araquidónico/farmacología , Presión Arterial/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Lipooxigenasa/fisiología , Frecuencia Respiratoria/efectos de los fármacos , Volumen de Ventilación Pulmonar/efectos de los fármacos , Animales , Análisis de los Gases de la Sangre , Dióxido de Carbono/sangre , Inyecciones Intraventriculares , Inhibidores de la Lipooxigenasa/farmacología , Masoprocol/farmacología , Oxígeno/sangre , Presión Parcial , Ratas
3.
Respir Physiol Neurobiol ; 242: 117-124, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28445779

RESUMEN

Arachidonic acid (AA), which is released from synaptic membrane phospholipid by neuroreceptor-initiated activation of phospholipase A2, is abundant in the brain and works as a neurotransmitter and/or neuromodulator in the central nervous system. Recently we reported that centrally injected AA generated pressor and hyperventilation effects by activating thromboxane A2 (TXA2) signaling pathway. The present study was designed to investigate the mediation of other metabolites of AA such as prostaglandin (PG) D, PGE and PGF2α alongside TXA2 in the AA-evoked cardiorespiratory effects in anaesthetized rats. Intracerebroventricular (i.c.v.) administration of AA caused pressor, bradycardic and hyperventilation responses by increasing pO2 and decreasing pCO2 in adult male anaesthetized Sprague Dawley rats. Pretreatment (i.c.v) with different doses of DP/EP prostanoid receptor antagonist, AH6809 or FP prostanoid receptor antagonist, PGF2α dimethylamine partially blocked the cardiorespiratory and blood gas changes induced by AA. In conclusion, these data plainly report that central PGD, PGE or PGF2α might mediate, at least partly, centrally administered AA-evoked cardiorespiratory and blood gas responses.


Asunto(s)
Ácido Araquidónico/farmacología , Fármacos Cardiovasculares/farmacología , Prostaglandinas D/metabolismo , Prostaglandinas E/metabolismo , Prostaglandinas F/metabolismo , Fármacos del Sistema Respiratorio/farmacología , Animales , Análisis de los Gases de la Sangre , Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/fisiología , Infusiones Intraventriculares , Masculino , Ratas Sprague-Dawley , Receptores de Prostaglandina/antagonistas & inhibidores , Receptores de Prostaglandina/metabolismo , Respiración/efectos de los fármacos , Tromboxano A2/metabolismo , Factores de Tiempo , Xantonas/farmacología
4.
Respir Physiol Neurobiol ; 225: 1-7, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-26767978

RESUMEN

Arachidonic acid (AA) is a polyunsaturated fatty acid that is present in the phospholipids of the cell membranes of the body and is abundant in the brain. Exogenously administered AA has been shown to affect brain metabolism and to exhibit cardiovascular and neuroendocrine actions. However, little is known regarding its respiratory actions and/or central mechanism of its respiratory effects. Therefore, the present study was designed to investigate the possible effects of centrally injected AA on respiratory system and the mediation of the central cyclooxygenase (COX) to thromboxane A2 (TXA2) signaling pathway on AA-induced respiratory effects in anaesthetized rats. Intracerebroventricular (i.c.v.) administration of AA induced dose- and time-dependent increase in tidal volume, respiratory rates and respiratory minute ventilation and also caused an increase in partial oxygen pressure (pO2) and decrease in partial carbon dioxide pressure (pCO2) in male anaesthetized Spraque Dawley rats. I.c.v. pretreatment with ibuprofen, a non-selective COX inhibitor, completely blocked the hyperventilation and blood gases changes induced by AA. In addition, central pretreatment with different doses of furegrelate, a TXA2 synthesis inhibitor, also partially prevented AA-evoked hyperventilation and blood gases effects. These data explicitly show that centrally administered AA induces hyperventilation with increasing pO2 and decreasing pCO2 levels which are mediated by the activation of central COX to TXA2 signaling pathway.


Asunto(s)
Ácido Araquidónico/farmacología , Prostaglandina-Endoperóxido Sintasas/metabolismo , Sistema Respiratorio/efectos de los fármacos , Sistema Respiratorio/enzimología , Tromboxano A2/metabolismo , Anestesia , Animales , Benzofuranos/farmacología , Dióxido de Carbono/sangre , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacología , Ibuprofeno/farmacología , Inyecciones Intraventriculares , Masculino , Oxígeno/sangre , Ratas Sprague-Dawley , Respiración/efectos de los fármacos , Fármacos del Sistema Respiratorio/farmacología , Volumen de Ventilación Pulmonar/efectos de los fármacos , Volumen de Ventilación Pulmonar/fisiología , Factores de Tiempo
5.
Auton Neurosci ; 193: 63-8, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26254710

RESUMEN

This study investigated the cardiovascular effects of nesfatin-1 in normotensive rats and animals subjected to hypotensive hemorrhage. Hemorrhagic hypotension was induced by withdrawal 2 mL blood/100 g body weight over a period of 10 min. Acute hemorrhage led to a severe and long-lasting decrease in mean arterial pressure (MAP) and heart rate (HR). Intracerebroventricularly (i.c.v.) administered nesfatin-1 (100 pmol) increased MAP in both normotensive and hemorrhaged rats. Nesfatin-1 also caused bradycardia in normotensive and tachycardia in hemorrhaged rats. Centrally injected nesfatin-1 (100 pmol, i.c.v.) also increased plasma catecholamine, vasopressin and renin concentrations in control animals and potentiated the rise in all three cardiovascular mediators produced by hemorrhage. These findings indicate that centrally administered nesfatin-1 causes a pressor response in conscious normotensive and hemorrhaged rats and suggest that enhanced sympathetic activity and elevated vasopressin and renin concentrations mediate the cardiovascular effects of the peptide.


Asunto(s)
Presión Sanguínea/efectos de los fármacos , Proteínas de Unión al Calcio/administración & dosificación , Fármacos del Sistema Nervioso Central/administración & dosificación , Proteínas de Unión al ADN/administración & dosificación , Frecuencia Cardíaca/efectos de los fármacos , Hipotensión/tratamiento farmacológico , Proteínas del Tejido Nervioso/administración & dosificación , Animales , Presión Sanguínea/fisiología , Bradicardia/fisiopatología , Catecolaminas/sangre , Modelos Animales de Enfermedad , Frecuencia Cardíaca/fisiología , Hemorragia/complicaciones , Hemorragia/fisiopatología , Hipotensión/etiología , Hipotensión/fisiopatología , Masculino , Nucleobindinas , Ratas Sprague-Dawley , Renina/sangre , Vasopresinas/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA